casno. : CAS 616202-92-7
Lorcaserin is a new type of drug for treating obesity, which is an effective oral selective 5-hydroxytryptamine 2C receptor agonist. Lorcaserin hydrochloride (BelviqTM) was successfully developed by Arena Company in the United States, and was approved by the US FDA to be listed on June 27, 2012 as an adjuvant treatment for obesity or overweight adult Chemicalbook people with at least one weight related complication on the basis of low calorie diet and exercise. Clinical studies have shown that the drug can effectively reduce the weight of obese and overweight patients, improve obesity related metabolic indicators, and is well tolerated. The affinity of 5-HT2c is 100 times higher than that of 5-HT2B (heart valve disease risk), and the safety is good. It is the first weight loss drug approved by FDA after 1999. The average weight loss during one year of treatment with chlorcatherine ranged from 3% to 3.7%.